Neumora Therapeutics Inc’s recently made public that its insider BERNS PAUL L unloaded Company’s shares for reported $23468.0 on Feb 18 ’25. In the deal valued at $1.69 per share,13,871 shares were sold. As a result of this transaction, BERNS PAUL L now holds 7,405,004 shares worth roughly $12.29 million.
Then, Milligan Michael Lee sold 1,978 shares, generating $3,351 in total proceeds. Upon selling the shares at $1.69, the insider now owns 22,470 shares.
Before that, Aurora Daljit Singh sold 8,565 shares. Neumora Therapeutics Inc shares valued at $14,347 were divested by the Chief Strategy Officer at a price of $1.68 per share. As a result of the transaction, Aurora Daljit Singh now holds 88,935 shares, worth roughly $0.15 million.
RBC Capital Mkts downgraded its Neumora Therapeutics Inc [NMRA] rating to a Sector perform from a an Outperform in a research note published on January 02, 2025; the price target was decreased to $4 from $29. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in early November from “an Overweight” to “a Neutral”. H.C. Wainwright began covering NMRA with “Buy” recommendation on October 01, 2024. Needham started covering the stock on July 22, 2024. It rated NMRA as “a Buy”.
Price Performance Review of NMRA
On Tuesday, Neumora Therapeutics Inc [NASDAQ:NMRA] saw its stock fall -2.92% to $1.66. Over the last five days, the stock has lost -4.05%. Neumora Therapeutics Inc shares have fallen nearly -84.34% since the year began. Nevertheless, the stocks have fallen -91.18% over the past one year. While a 52-week high of $21.00 was reached on 01/07/25, a 52-week low of $1.60 was recorded on 02/12/25. SMA at 50 days reached $4.4453, while 200 days put it at $9.6461.
Levels Of Support And Resistance For NMRA Stock
The 24-hour chart illustrates a support level at 1.6117, which if violated will result in even more drops to 1.5633. On the upside, there is a resistance level at 1.7067. A further resistance level may holdings at 1.7533. The Relative Strength Index (RSI) on the 14-day chart is 25.67, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0352, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.62%. Stochastics %K at 31.62% indicates the stock is a holding.
The most recent change occurred on July 08, 2024 when Mizuho began covering the stock and recommended ‘”an Outperform”‘ rating along with a $20 price target.
